Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older
- People who have given their informed consent to participate
- People who have been confirmed through a tissue sample (biopsy) to have breast cancer (either invasive or non-invasive) or a phyllodes tumour (a rare type of breast tumour)
- People who have previously had breast cancer on the same side of the body that was treated with radiation therapy
- People who are planned to receive a specific type of radiation treatment called hypofractionated radiotherapy (a course of 40Gy delivered in 15 sessions) to the whole breast, part of the breast, or the chest wall
- People who are receiving their radiation treatment with or without an additional targeted radiation boost or a bolus (a material placed on the skin during treatment)
- People who are receiving radiation treatment to the local breast area or to a broader surrounding region
- People who are able to communicate in English, or who have access to a translator to assist them
Who may not be able to join:
- People who are planned to receive a different radiation schedule, either the standard course (50Gy in 25 sessions or 45Gy in 25 sessions) or a very short course (26Gy in 5 sessions)
- People who are planned to receive a type of internal radiation treatment called brachytherapy
- People who have an active skin rash, existing skin inflammation, or other skin conditions in the area to be treated that could make it difficult to assess the skin during the study, as determined by the treating doctor
- People who are receiving cytotoxic chemotherapy (a type of cancer-killing drug treatment) at the same time as their radiation therapy
- People who have a condition called scleroderma (a disease that affects the skin and connective tissue)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Effects of hypofractionated reRT (40Gy in 15 fractions) on acute skin toxicity
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.